You are here

Our science / Clinical Trials / Find a Trial / NCT02104557

Post Marketing Surveillance Study For Sayana®

Back to Search Print Save as PDF Bookmark Trial

NCT02104557

Last updated on December 6, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Inje University Haeundae Paik Hospital
Haeundae-gu, Busan, 48108 Korea, Republic of
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Postmarketing Product Surveillance
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects or legally authorized representatives of pediatric subjects agree to provide
written informed consent form (ie, data privacy statement).

2.Women subjects who are initiating treatment with Sayana® for the first time as per the
local product document for usage

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Known or suspected pregnancy.

- Undiagnosed vaginal bleeding.

- Known or suspected malignancy of breast.

- Active thrombophlebitis, or current or past history of thromboembolic disorders, or
cerebral vascular disease.

- Significant liver disease.

- Known hypersensitivity to medroxyprogesterone acetate or any of its other ingredients.

- Women who are before menarche or who are post-menopausal.

- Treatment with any investigational agent or device within 30 days prior to the
enrollment visit.

NCT02104557
Pfizer
Recruiting
Post Marketing Surveillance Study For Sayana®

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Similar Trials

Postmarketing Product Surveillance
Post Marketing Surveillance Study For Sayana®
NCT02104557
Females
0+
Years
Multiple Sites
Epilepsy, Neuropathic Pain, Fibromyalgia, Post-market Surveillance
Lyrica (Pregabalin) Korean Post Marketing Surveillance Study
NCT01220180
All Genders
Post Marketing Surveillance Study For Sayana®
Post Marketing Surveillance To Observe Safety And Efficacy Of Sayana(Registered) Used For Contraception And Management Of Endometriosis-associated Pain
Post Marketing Surveillance To Observe Safety And Efficacy Of Sayana® Used For Contraception And Management Of Endometriosis-Associated Pain
Post Marketing Surveillance required by Korea MFDS regulation. Select among patients who randomly visit the site who meet the inclusion/exclusion criteria.
Observational
Observational Model: Other
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Women subjects who are initiating treatment with Sayana® for the first time as per the local product document for usage
Product Surveillance, Postmarketing
Other: Non intervention
Non intervention
  • prevention of pregnancy
    Non intervention
    Intervention: Other: Non intervention
  • management of endometriosis-associated pain
    Non intervention
    Intervention: Other: Non intervention
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
600
October 28, 2018
October 28, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

- Subjects or legally authorized representatives of pediatric subjects agree to provide written informed consent form (ie, data privacy statement).

2.Women subjects who are initiating treatment with Sayana® for the first time as per the local product document for usage

Exclusion Criteria:

  • Known or suspected pregnancy.
  • Undiagnosed vaginal bleeding.
  • Known or suspected malignancy of breast.
  • Active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease.
  • Significant liver disease.
  • Known hypersensitivity to medroxyprogesterone acetate or any of its other ingredients.
  • Women who are before menarche or who are post-menopausal.
  • Treatment with any investigational agent or device within 30 days prior to the enrollment visit.
Sexes Eligible for Study: Female
Gender Based Eligibility: Yes
Child, Adult, Senior
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Korea, Republic of
 
 
NCT02104557
A6791036
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now